Gilead Sciences Inc logo

Gilead Sciences Inc

$ 84.50 +3.11 (+3.82%) 11:08 PM EST
On watch
P/E:
23.15
P/B:
4.97
Market Cap:
$ 105.37B
Enterprise V:
$ 124.93B
Volume:
12.81M
Avg Vol (2M):
7.14M
Also Trade In:
Volume:
12.81M
Market Cap $:
105.37B
PE Ratio:
23.15
Avg Vol (2-Month):
7.14M
Enterprise Value $:
124.93B
PB Ratio:
4.97
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Gilead Sciences Inc ( ) from 1992 to Feb 05 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Gilead Sciences stock (GILD) PE ratio as of Feb 05 2023 is 23.15. More Details

Gilead Sciences Inc (GILD) PE Ratio (TTM) Chart

To

Gilead Sciences Inc (GILD) PE Ratio (TTM) Historical Data

Total 1224
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Gilead Sciences PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2023-02-05 23.1 2022-11-30 33.1
2023-02-03 23.1 2022-11-29 32.4
2023-02-02 22.3 2022-11-28 32.1
2023-02-01 23.0 2022-11-25 32.5
2023-01-31 23.0 2022-11-23 32.2
2023-01-30 22.8 2022-11-22 32.2
2023-01-27 22.9 2022-11-21 31.8
2023-01-26 22.9 2022-11-18 31.6
2023-01-25 23.0 2022-11-17 31.6
2023-01-24 23.0 2022-11-16 31.3
2023-01-23 22.8 2022-11-15 31.3
2023-01-20 22.7 2022-11-14 31.3
2023-01-19 22.9 2022-11-11 30.9
2023-01-18 22.9 2022-11-10 31.2
2023-01-17 23.4 2022-11-09 31.1
2023-01-13 23.6 2022-11-08 31.0
2023-01-12 23.5 2022-11-07 30.7
2023-01-11 23.9 2022-11-04 30.3
2023-01-10 23.9 2022-11-03 30.0
2023-01-09 23.3 2022-11-02 29.4
2023-01-06 24.1 2022-11-01 29.9
2023-01-05 23.5 2022-10-31 29.6
2023-01-04 23.4 2022-10-28 29.9
2023-01-03 23.4 2022-10-27 26.5
2022-12-30 23.5 2022-10-26 26.7
2022-12-29 23.4 2022-10-25 26.3
2022-12-28 23.2 2022-10-24 26.0
2022-12-27 32.1 2022-10-21 25.6
2022-12-23 32.0 2022-10-20 25.0
2022-12-22 32.2 2022-10-19 25.0
2022-12-21 32.2 2022-10-18 25.2
2022-12-20 32.0 2022-10-17 25.1
2022-12-19 32.6 2022-10-14 25.0
2022-12-16 32.7 2022-10-13 25.1
2022-12-15 32.7 2022-10-12 24.7
2022-12-14 33.4 2022-10-11 24.8
2022-12-13 33.5 2022-10-10 24.3
2022-12-12 33.4 2022-10-07 24.3
2022-12-09 33.2 2022-10-06 24.5
2022-12-08 33.8 2022-10-05 24.7
2022-12-07 33.1 2022-10-04 24.6
2022-12-06 33.2 2022-10-03 23.5
2022-12-05 33.2 2022-09-30 23.3
2022-12-02 33.6 2022-09-29 23.8
2022-12-01 33.2 2022-09-28 24.1

Gilead Sciences Inc (GILD) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.